Frontlight ResearchEarly access
Kidney cancer trials in Germany
13 of 19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Where
- Augsburg, Berlin, Heidelberg, Jena, Munich
- Age
- 18 years and over
- People
- 758 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07489495 · EU 2024-516993-31-00 - Phase 3Taking peopleA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Where
- Berlin, Dresden, Erfurt, Goettingen, Hamburg, Herne, Jena, Muenster, Nuertingen, Rostock, Schwerin, Stuttgart, Tuebingen
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07227402 · EU 2024-517136-21-00 - Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Magdeburg
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 3Taking peopleStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Halle Saale, Hanover, Heidelberg, Leipzig, Luebeck, Marburg, Rostock, Ulm
- Age
- 18 years and over
- People
- 720 worldwide
- Run by
- Arcus Biosciences, Inc.
See details and how to joinNCT07011719 · EU 2024-515023-11-00 - Phase 1/2Not yet taking people in GermanyA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Where
- Hamburg, Herne, Jena, Munich
- Age
- 18 years and over
- People
- 474 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07293351 · EU 2026-527163-15-00 - Phase 1Taking peopleKO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Where
- Berlin, Ulm, Wuerzburg
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00 - Phase 1/2Taking peopleSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Where
- Berlin, Dresden, Essen, Heidelberg
- Age
- 18 years and over
- People
- 224 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227415 · EU 2025-523524-53-00 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 1Not yet taking people in GermanyA Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
- Where
- Essen, Jena
- Age
- 18 years and over
- People
- 112 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07848295 - Phase 3Taking peopleCARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
- Where
- Duesseldorf, Essen, Frankfurt Am Main, Hanover, Heidelberg, Herne, Munich, Münster, Stuttgart, Tübingen
- Age
- 18 years and over
- People
- 1,373 worldwide
- Run by
- Institut Gustave Roussy
See details and how to join2023-503317-29-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Dresden, Essen, Frankfurt, Ulm, Würzburg
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1/2Not yet taking people in GermanyA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Bonn, Erlangen, Essen, Hamburg, Heilbronn
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Hamburg
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767